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Abstract
Chronic idiopathic constipation (CIC) can be defined as bowel movements that are difficult to
pass, are not occurring frequently, or have incomplete evacuation during defecation. A high-
fiber diet and laxatives are the commonly used treatments, but in many cases, they do not
produce satisfactory results. The first line of treatment is osmotic laxatives. If there is no
improvement, the second line is guanylate cyclase-C (GCC) agonists like linaclotide or
prokinetic agents such as prucalopride. On December 14, 2018, the United States Food and Drug
Administration (US FDA) approved prucalopride for treating chronic idiopathic constipation.
Prucalopride is a prokinetic agent which works at the 5-hydroxytryptamine receptor 4 (5-HT4)
as an agonist with greater receptor selectivity. Patients on prucalopride reported improved
symptoms, quality of life and satisfaction. The most frequent adverse events were headaches
and problems related to the gastrointestinal tract. Caution should be taken when using
prucalopride in patients with impaired liver and renal function. In Canada, prucalopride has
been approved for treatment of female patients with chronic idiopathic constipation who have
failed therapy with at least two laxatives from different classes over a six-month period.
Categories: Internal Medicine, Gastroenterology, Epidemiology/Public Health
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Introduction And Background
Chronic idiopathic constipation (CIC) can be defined as bowel movements that are difficult to
pass, are not occurring frequently, or have incomplete evacuation during defecation. According
to the Rome IV criteria, constipation should be present for three months with the onset of
symptoms at least six months before for making a diagnosis [1]. It should also include two or
more of the following symptoms in more than one-fourth of defecations: straining, hard stools,
the sensation of anorectal obstruction, incomplete evacuation, use of manual maneuvers for
bowel evacuation or less than three spontaneous bowel movements in a week. Furthermore,
irritable bowel syndrome should be ruled out and there should be rare occurrence of loose
stools without laxative use. There are three types of chronic idiopathic constipation. The first
type is normal-transit constipation (stool takes one and a half to three days to pass through the
colon) [2]. Second is slow-transit constipation (stool takes more than five days to pass through
the colon, also called colonoparesis) [3]. Third is outlet dysfunction (it is associated with a
sense of incomplete evacuation) [4]. Everhart et al. concluded a positive relationship between
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constipation and low socioeconomic status [5]. This condition can significantly impact a
person's quality of life and productivity. In the majority of cases, the condition is initially
treated empirically without investigation for a cause. High-fiber diet and laxatives are the
commonly used treatments, but in many cases, they do not produce satisfactory results [6].
These patients are then treated by other medications, behavioral therapy, or surgical
intervention. In CIC with slow transit, the first line of treatment is osmotic laxatives. If there is
no improvement, the second line is guanylate cyclase-C (GCC) agonists like linaclotide or
prokinetic agents such as prucalopride [7]. On December 14, 2018, the United States Food and
Drug Administration (US FDA) approved prucalopride for treating chronic idiopathic
constipation [8]. The aim of our study is to review the published literature on the clinical
efficacy and safety of prucalopride in treating chronic idiopathic constipation.
Review
Mechanism of action
Prucalopride is a prokinetic agent which works at the 5-hydroxytryptamine receptor 4 (5-HT4)
as an agonist with greater receptor selectivity and less proarrhythmic risk as compared to other
members of its class [9]. The role of prucalopride in improving constipation is attributed to its
ability to increase the number of synchronous contractions in the large intestine and
simultaneously decrease the frequency of isolated contractions in the proximal colon [10]. It
stimulates giant migratory contractions in the colon, the lack of which is a possible underlying
mechanism for CIC. Increasing gastrointestinal motility is especially beneficial for patients of
chronic constipation who lack these high amplitude propagating contractions (HAPS). These
prokinetic effects are not limited to the large bowel. It also accelerates gastric emptying and
small bowel transit [11].
Recommended Dose
It is generally given at a dose of 2-4 mg/day in patients with CIC. However, the recommended
dose for elderly patients is 1 mg [12].
Clinical efficacy and quality of life
Patients on prucalopride reported improved symptoms, quality of life, and satisfaction. In a
phase III study by Quigley et al. including 641 patients with severe chronic constipation, 24%
patients taking prucalopride as compared to 12% in the placebo group achieved three or more
spontaneous complete bowel movements (SCBMs) per week [13].
Camilleri et al. studied the efficacy of prucalopride in patients with chronic constipation.
Patients from three double-blind, placebo-controlled, 12-week studies with prucalopride were
allowed to continue treatment in open-label studies up to 24 months. Out of the 1,455 patients
who completed the primary studies, 86% continued with the prucalopride. The improvement in
the Patient Assessment of Constipation Quality of Life questionnaire (PAC-QOL) satisfaction
score seen after a 12-week treatment was preserved in the open-label treatment for up to 18
months [14].
In a randomized, double-blind, phase 3 study by Yiannakou et al. including 374 patients, 142
(37.9%) patients achieved a mean of three or more SCBMs per week in the prucalopride group as
compared to 67 (17.7%) patients in the placebo group (p <0.0001). The proportion of patients
with an improvement of at least one point in Patient Assessment of Constipation Quality of
Life questionnaire (PAC-QOL) satisfaction subscale score was 52.7% and 38.8% in the
prucalopride and placebo groups, respectively (p = 0.0035) [15].
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An integrated analysis of six randomized clinical trials was done by Camilleri et al to determine
the efficacy of prucalopride in patients with chronic constipation. A total of 2,484 patients
including 597 men and 1,887 women were included in the study. Of this, 27.8% in the
prucalopride group as compared to 13.2% in the placebo group when treated over 12 weeks
achieved a mean of ≥3 SCBMs/week (p < 0.001) [16].
Safety profile
In a study by Camilleri et al. including 1,455 patients, the most frequent adverse events were
headaches (1%) and problems related tothe gastrointestinal tract (3.3%) [14]. Another trial to
determine the safety of prucalopride in older patients with chronic constipation who are living
in nursing homes was done. Most of the patients included in this study had a history of
cardiovascular disease. Only one female who had a history of pacemaker and heart disease
showed prolongation of QT interval from baseline [17]. Caution should be taken when using
prucalopride in patients with impaired liver function and renal function. Since it is excreted in
the urine unchanged, the dose is reduced to 1 mg once daily in patients with impaired renal
function [18]. It is also not recommended for use during pregnancy or lactation (category C
drug) [19].
Chronic Constipation Diagnosis and Treatment Evaluation: (CHRO.CO.DI.T.E. Study)
Bellini et al. focused on the different diagnostic and therapeutic options considered by Italian
gastroenterologists in patients with chronic constipation, especially constipation-predominant
irritable bowel syndrome. Most of them used Macrogol, a laxative, as the first line of treatment
along with lifestyle modifications and an increased fiber diet. Prucalopride was used mainly as
a second or third line of treatment due to its high cost [20].
Other clinical implications of prucalopride
Prucalopride can be used for treating constipation in patients with chronic opioid use and
spinal cord injury [21-22]. A placebo-controlled phase II trial demonstrated that over a four-
week period, 40.3% compared to 23.4% of patients with opioid-induced bowel dysfunction
(OIBD) achieved an increase of ≥1 spontaneous bowel movement per week from baseline with
prucalopride (4 mg) as compared to placebo, respectively (p = 0.002) [22].
Prucalopride is also effective in reducing post-operative complications. A phase II randomized
clinical trial was conducted on 110 post-op patients who had undergone elective
gastrointestinal surgery. Fifty-five patients were treated with oral prucalopride (2 mg/day) and
the other 55 were given placebo. Patients treated with prucalopride had a shorter time to
defecation (65.0 vs. 94.5 h, p = 0.001), passage of flatus (53.0 vs. 73.0 h, p < 0.001), and
postoperative length of stay (7.0 vs. 8.0 days, p = 0.001) than controls [23].
Prucalopride can be used for the purpose of bowel cleansing before colonoscopy. Corleto et al.
demonstrated that the colon cleansing was optimal in 87% of the patients who were treated
with combined prucalopride and 1L polyethylene glycol (PEG) solution instead of the 2L which
is normally used. Two patients that used prucalopride reported mild headaches. Therefore,
prucalopride can be used for bowel preparation in patients who are unable to drink large
quantities of PEG solution [24].
Cinca et al. compared prucalopride with polyethylene glycol-3350 with electrolytes (PEG
3350+E), an osmotic laxative. Two groups of 120 patients each were given prucalopride and PEG
3350+E respectively for four weeks. In the per-protocol population, 66.67% patients in the PEG
3350+E group compared to 56.52% in the prucalopride group achieved more than three SCBMS
per week. In the modified intention to treat population, similar results were found but there
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was more improvement in abdominal symptoms with prucalopride after the first week of
treatment. The limiting factor was the length of the study which was only four weeks. Further
studies have to be done to determine the long-term efficacy of both therapies [25].
Although many treatment options are common for both constipation-predominant IBS (IBS-C)
and CIC like lubiprostone, linaclotide and the older 5-hydroxytryptamine receptor 4 (5-HT4)
agonists (tegaserod), some therapies have shown a better response in one group as compared to
other. For instance, IBS-C patients respond well to treatments that are specific to pain like
antidepressants and cognitive behavioral therapy, whereas prucalopride and pelvic floor
biofeedback has more efficacy in CIC group [26].
Prucalopride has shown efficacy in patients with systemic sclerosis (SSc) intestinal disease. In a
study by Vigone et al. including 40 patients, 29 participants completed the study. Prucalopride
was significantly associated with more intestinal evacuations (p < 0.001) and improvements in
reflux (p < 0.005) and bloating (p = 0.01) scores [27].
Prucalopride has also shown efficacy in pediatric constipation. Cisapride, a 5-HT4 receptor
agonist was previously approved for childhood constipation, but due to its implication in
serious cardiac adverse effects such as arrythmias and sudden death, it was withdrawn. Children
given a single dose of prucalopride 0.03 mg/kg (approximately equivalent to a 2 mg dose in an
adult weighing 70 kg) had identical pharmacokinetics as studied in adults except for a lower
systemic clearance. Children with CIC when treated with prucalopride over eight weeks had a
mean frequency of 6.8 bowel movements per week, improvement in stool consistency, and a
decrease in frequency of fecal incontinence [28].
In Canada, prucalopride has been approved for the treatment of female patients with chronic
idiopathic constipation who have failed therapy with at least two laxatives from different
classes over a six-month period. It is the only agent that is recommended by the National
Institute for Health Care Excellence (NICE) for chronic constipation in women [29]. Table 1
below shows the adverse effects of prucalopride compared to other drugs used in chronic
constipation, and Table 2 below shows the efficacy of prucalopride and other drugs used in
chronic constipation.
Drugs Adverse Effects Referencenumber
Prucalopride Abdominal pain, diarrhea, nausea, and headache [14]
Velusetrag Diarrhea, headache, nausea, vomiting, flatulence, and abdominal pain [30]
Lubiprostone Vomiting, nausea, and abdominal cramping [31]
Linaclotide Diarrhea [32]
Plecanatide Diarrhea, sinusitis, upper respiratory tract infection, abdominal distension, flatulence,abdominal tenderness, and increased levels on liver biochemical tests [33]
TABLE 1: Comparison of adverse effects of prucalopride with other drugs used in
chronic constipation
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Drugs CSBM SBM Reference number
Prucalopride 1.4 4.9 [22]
Velusetrag 2 3.5 [30]
Lubiprostone 2.6 3.2 [34, 35]
Linaclotide 1.8 4.8 [36, 37]
Plecanatide 2.2 3.1 [38]
TABLE 2: Efficacy of prucalopride and other drugs used in chronic constipation in
terms of CSBM and SBM
CSBM; Complete spontaneous bowel movements, SBM; Short bowel movements
Conclusions
Prucalopride is a very useful alternate agent in patients with chronic constipation who have
failed laxative therapy and has also been approved for use in Canada. Due to its highly selective
action on 5-HT4 serotonin receptor, it is very well-tolerated with fewer cardiac adverse effects.
However, randomized prospective trials involving larger populations are needed to further
explore the efficacy and safety profile of prucalopride.
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